Literature DB >> 26449970

Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma.

L Mastalerz1, N Celejewska-Wójcik1, K Wójcik1, A Gielicz1, A Ćmiel2, M Ignacak1, K Oleś1, A Szczeklik2, M Sanak1.   

Abstract

BACKGROUND: Induced sputum (IS) allows to measure mediators of asthmatic inflammation in bronchial secretions. The specific role of induced sputum supernatant (ISS) endogenous bioactive lipid mediators in subtypes of asthma is not well understood.
OBJECTIVE: To investigate the interactions between airway inflammation and clinical phenotypes of asthma, we integrated induced sputum supernatant (ISS) eicosanoids and quantitative assessment of infiltrating cells into new subtypes with the means of latent class analysis (LCA).
METHODS: One hundred and thirty-nine asthmatics with and without aspirin hypersensitivity underwent sputum induction. High-performance liquid chromatography or gas chromatography coupled with mass spectrometry was used to profile eicosanoids. Nineteen variables covering clinical characteristics, IS inflammatory cells and eicosanoids were considered in the LCA.
RESULTS: Four phenotypic asthma classes were distinguished. Class 1 with mild-to-moderate asthma, chronic rhinosinusitis (CRS), high PGA2 in ISS and almost equal distribution of inflammation cell patterns. Class 3 subjects also had mild-to-moderate asthma but without upper airway symptoms. Induced sputum was often paucigranulocytic with low levels of lipid mediators. Classes 2 and 4 represented severe asthma with CRS and impaired lung function despite high doses of steroids. High blood and sputum eosinophilia was in line with high cysteinyl leukotrienes and PGD2 in ISS only in class 2. Class 4 subjects tended to have increased sputum neutrophilia and PGE2 in ISS. Aspirin hypersensitivity was most frequent among class 2 subjects. CONCLUSIONS & CLINICAL RELEVANCE: The LCA revealed four distinct asthma classes differing in eicosanoid pathways.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma phenotype; eicosanoids; induced sputum; latent class analysis

Mesh:

Substances:

Year:  2015        PMID: 26449970     DOI: 10.1111/cea.12654

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  10 in total

1.  Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic.

Authors:  Agnieszka Gawlewicz-Mroczka; Adam Pytlewski; Natalia Celejewska-Wójcik; Adam Ćmiel; Anna Gielicz; Marek Sanak; Lucyna Mastalerz
Journal:  Clin Transl Allergy       Date:  2022-10-19       Impact factor: 5.657

Review 2.  Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Lucyna Mastalerz; Katarzyna E Tyrak
Journal:  Clin Transl Allergy       Date:  2021-08-13       Impact factor: 5.871

Review 3.  Eicosanoid Mediators in the Airway Inflammation of Asthmatic Patients: What is New?

Authors:  Marek Sanak
Journal:  Allergy Asthma Immunol Res       Date:  2016-11       Impact factor: 5.764

4.  Artificial neural network identifies nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N-ERD) cohort.

Authors:  Katarzyna Ewa Tyrak; Kinga Pajdzik; Ewa Konduracka; Adam Ćmiel; Bogdan Jakieła; Natalia Celejewska-Wójcik; Gabriela Trąd; Adrianna Kot; Anna Urbańska; Ewa Zabiegło; Radosław Kacorzyk; Izabela Kupryś-Lipińska; Krzysztof Oleś; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
Journal:  Allergy       Date:  2020-03-03       Impact factor: 13.146

5.  Subphenotypes of nonsteroidal antiinflammatory disease-exacerbated respiratory disease identified by latent class analysis.

Authors:  Natalia Celejewska-Wójcik; Krzysztof Wójcik; Maria Ignacak-Popiel; Adam Ćmiel; Katarzyna Tyrak; Anna Gielicz; Aleksander Kania; Paweł Nastałek; Marek Sanak; Lucyna Mastalerz
Journal:  Allergy       Date:  2020-01-28       Impact factor: 13.146

6.  Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2).

Authors:  Mario Castro; Edward Kerwin; David Miller; Andrew Pedinoff; Lawrence Sher; Pamela Cardenas; Barbara Knorr; David Lawrence; Diego Ossa; Wei Wang; Jorge F Maspero
Journal:  EClinicalMedicine       Date:  2021-04-25

7.  Thrombin Induces COX-2 and PGE2 Expression via PAR1/PKCalpha/MAPK-Dependent NF-kappaB Activation in Human Tracheal Smooth Muscle Cells.

Authors:  Chien-Chung Yang; Li-Der Hsiao; Ya-Fang Shih; Chih-Kai Hsu; Chia-Yu Hu; Chuen-Mao Yang
Journal:  Mediators Inflamm       Date:  2022-04-19       Impact factor: 4.529

8.  Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Authors:  Bart Hilvering; Timothy S C Hinks; Linda Stöger; Emanuele Marchi; Maryam Salimi; Rahul Shrimanker; Wei Liu; Wentao Chen; Jian Luo; Simei Go; Timothy Powell; Jennifer Cane; Samantha Thulborn; Ayako Kurioka; Tianqi Leng; Jamie Matthews; Clare Connolly; Catherine Borg; Mona Bafadhel; Christian B Willberg; Adaikalavan Ramasamy; Ratko Djukanović; Graham Ogg; Ian D Pavord; Paul Klenerman; Luzheng Xue
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

9.  Eicosanoids and Eosinophilic Inflammation of Airways in Stable COPD.

Authors:  Natalia Celejewska-Wójcik; Aleksander Kania; Karolina Górka; Paweł Nastałek; Krzysztof Wójcik; Anna Gielicz; Lucyna Mastalerz; Marek Sanak; Krzysztof Sładek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-05-25

10.  Local and Systemic Production of Pro-Inflammatory Eicosanoids Is Inversely Related to Sensitization to Aeroallergens in Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Daniel P Potaczek; Gabriela Trąd; Marek Sanak; Holger Garn; Lucyna Mastalerz
Journal:  J Pers Med       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.